M. McKean, S. Kato, A. Spira, Yan Xing, Hao Xie, E. Buchbinder, Ken Kobayashi, Richard Williams
{"title":"P226:一项首次人体(FIH) 1/1b期研究的设计和基本原理,该研究评估了KIN-2787(一种强效、高选择性的泛raf抑制剂)在BRAF突变阳性实体瘤成年患者中的作用","authors":"M. McKean, S. Kato, A. Spira, Yan Xing, Hao Xie, E. Buchbinder, Ken Kobayashi, Richard Williams","doi":"10.1158/1535-7163.targ-21-p226","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"90 10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract P226: Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors\",\"authors\":\"M. McKean, S. Kato, A. Spira, Yan Xing, Hao Xie, E. Buchbinder, Ken Kobayashi, Richard Williams\",\"doi\":\"10.1158/1535-7163.targ-21-p226\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20348,\"journal\":{\"name\":\"Poster Presentations - Proffered Abstracts\",\"volume\":\"90 10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Presentations - Proffered Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1535-7163.targ-21-p226\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Presentations - Proffered Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.targ-21-p226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P226: Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors